Author:

  • All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Announcements 2025
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

Paiania, 14 April 2025 - Lavipharm S.A. is pleased to announce the establishment of a joint company in partnership with Tikun Olam Europe. This collaboration will introduce telemedicine services via a telemedicine mediation application, in compliance with Article 1 of Ministerial Decision 7686/10.3.25. The primary...

(Unaudited Financial Data) Significant Sales and EBITDA Growth – Strong increase in net profit   Paiania, 19 March 2025 - Lavipharm S.A. informs the investment community on the key financial figures for the fiscal year 2024, as well as the Group’s operational developments to date: Consolidated Sales from ongoing...

Paiania, 14 March 2025 – Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2025, as follows:   Wednesday, 19 March 2025 Flash Note on Financial Results of FY 2024 Thursday, 3 April 2025 Announcement of FY 2024 Financial Report Thursday, 24...

Paiania, 4 February 2025 – Lavipharm S.A., a Pharmaceutical, Chemical, and Cosmetic Products Commercial and Industrial Societe Anonyme (hereinafter the “Company”), announces, in accordance with the provisions of Article 19 of Regulation (EU) No. 596/2014 and following a relevant notification received, that on 3 February...

Παιανία, 23 Δεκεμβρίου 2024 - Η Lavipharm A.E., σε συνέχεια της από 14.02.2024 ανακοίνωσής της σχετικά με τη διακοπή της δραστηριότητας  φαρμακαποθήκης και υπηρεσιών logistics προς τρίτους  (3PL) του Ομίλου και τη μεταβίβαση ορισμένων περιουσιακών στοιχείων της θυγατρικής της εταιρείας LAS, ενημερώνει το επενδυτικό κοινό...

Peania, 23 January 2025 – Lavipharm announces a strategic commercial agreement with the multinational company iNova Pharmaceuticals, the owner of Betadine® and other trusted brands. The new partnership involves the licensing rights of a new antiseptic pharmaceutical OTC product developed by Lavipharm to be commercialized by...

Paiania, 19 September 2024 – Lavipharm reports an increase in consolidated sales in H1 2024. Specifically, consolidated Sales from continuing operations amounted to EUR 30.6 million, compared to EUR 29.1 million in the corresponding period of 2023, for an increase of 5.3%. Consolidated Sales, after...

Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 4 θ΄) αναφορικά με την Διάθεση Νέων Κοινών Ονομαστικών Μετοχών της Εταιρείας με την επωνυμία «Ανώνυμη Εμπορική και Βιομηχανική Εταιρία Φαρμακευτικών, Χημικών και Καλλυντικών Προϊόντων LAVIPHARM A.E.» Παιανία, 12 Ιουλίου 2024 – H ανώνυμη εταιρεία με την...